Format

Send to

Choose Destination
J Rheumatol. 1992 Sep;19(9):1403-6.

Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.

Author information

1
Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, UK.

Abstract

Iloprost is a chemically stable analog of prostaglandin I2 showing the same properties as the naturally occurring substance, but with advantages of ease of handling and administration to patients. A double blind within patient comparison of intravenous iloprost and placebo was undertaken in 13 patients with Raynaud's phenomenon severe enough to warrant short term hospitalization for intravenous dilator therapy; thermography was used as one form of assessment. Our results, while showing improvements in frequency of Raynaud's attacks after iloprost compared with placebo, show no significant effects on other variables.

PMID:
1279169
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center